Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 2/20 | 0.41 |
| ▸ | CPA1 | P15085 | 1/20 | 0.41 |
| ▸ | CPB1 | P15086 | 1/20 | 0.41 |
| ▸ | CPA2 | P48052 | 1/20 | 0.41 |
| ▸ | CPA4 | Q9UI42 | 1/20 | 0.41 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
| ▸ | MME | P08473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6412346 | 0.90 | CPA1 (0.45) | CPA1CPB1CPA2CPA4ACE2 | |
| SCHEMBL6417816 | 0.88 | ECE1 (0.40) | CPA1CPB1CPA2CPA4ACE2 | |
| SCHEMBL6414339 | 0.87 | ECE1 (0.39) | CPA1CPB1CPA2CPA4ACE2 | |
| SCHEMBL6412734 | 0.87 | CPA1 (0.39) | CPA1CPB1CPA2CPA4ACE2 | |
| SCHEMBL7316834 | 0.85 | CPA1 (0.40) | CPA1CPB1CPA2CPA4ACE2 | |
| SCHEMBL7321038 | 0.84 | MMP1 (0.49) | MMP1 | |
| SCHEMBL7325571 | 0.83 | SLC1A3 (0.45) | ACE2MME | |
| SCHEMBL6257526 | 0.82 | LTA4H (0.40) | CPA1CPB1CPA2CPA4ACE2 | |
| SCHEMBL7323541 | 0.82 | ANPEP (0.38) | CPA1CPB1CPA2CPA4ACE2 | |
| SCHEMBL7320171 | 0.81 | CPA1 (0.41) | CPA1CPA2CPA4ACE2LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040192658-A1 | Compositions and methods of using collajolie | ANGIOTECH INTERNATIONAL AG (CH) | 2004-09-30 | — | — | US | disclosed |
| US-20030181371-A1 | Compositions and methods of using collajolie | ANGIOTECH PHARMACEUTICALS, INC. (CA) | 2003-09-25 | — | — | US | disclosed |
| US-20030087863-A1 | Activation matrix metalloprotease; diagnosis of disease sensitivity; rheumatic diseases, bone disorders | MOUNT SINAI SCHOOL OF MEDICINE | 2003-05-08 | — | — | US | disclosed |
| US-20020037827-A1 | Novel matrix metalloproteinase (MMP-25) expressed in skin cells | DARWIN MOLECULAR CORPORATION | 2002-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192658-A1 | Compositions and methods of using collajolie | MMP9, COL2A1, MMP1 | MMP1 3/4885CPA1 62/4885CPB1 91/4885 |
| US-20030181371-A1 | Compositions and methods of using collajolie | MMP1, COL2A1, COL14A1 | MMP1 1/4885CPA1 52/4885CPB1 83/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.